Phase I trial of N-(Phosphonacetyl)-L-aspartic acid (PALA).
N-(Phosphonacetyl)-L-aspartic acid (PALA) was given as a 5-day continuous infusion in a phase I trial. Dose-limiting toxic effects noted were diarrhea occurring at doses of greater than or equal to 6 g/m2/course, mucositis occurring at doses of greater than or equal to 7.5 g/m2/course, and skin rash occurring at doses greater than 9 g/m2/course. No significant CNS, hemorrhagic, gastrointestinal, or hematologic toxicity was noted. In patients with measurable tumor volume, no significant antitumor responses were seen. A dose of 9 g/m2/course is recommended for a phase II trial.
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use / Q000633:toxicity*; D001224:Aspartic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use / Q000633:toxicity; D003967:Diarrhea / Q000139:chemically induced; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D006801:Humans; D007263:Infusions, Parenteral; D008875:Middle Aged; D009092:Mucous Membrane / Q000187:drug effects; D009369:Neoplasms / Q000188:drug therapy; D009943:Organophosphorus Compounds / Q000633:toxicity*; D010746:Phosphonoacetic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use / Q000633:toxicity*; D012871:Skin Diseases / Q000139:chemically induced
D000970:Antineoplastic Agents; D009943:Organophosphorus Compounds; D001224:Aspartic Acid; C013195:sparfosic acid; D010746:Phosphonoacetic Acid